Clinical Trial: Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07153497) titled 'Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)' on Sept. 03.

Brief Summary: This phase II MyeloMATCH treatment trial studies how well the addition of olutasidenib to usual treatment with cedazuridine-decitabine (ASTX727) with or without venetoclax works in treatment patients with higher-risk myelodysplastic syndrome (MDS) with a mutation in the IDH1 gene. Olutasidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. Ceda...